Barclays Lowers Bruker (NASDAQ:BRKR) Price Target to $45.00

Posted by Stanley Muller on Apr 14th, 2026

Bruker (NASDAQ:BRKR – Get Free Report) had its price target dropped by investment analysts at Barclays from $50.00 to $45.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the medical research company’s stock. Barclays‘s price target would indicate a potential upside of 12.78% from the stock’s current price.

A number of other research firms have also weighed in on BRKR. Jefferies Financial Group set a $50.00 price objective on Bruker in a research report on Thursday, February 12th. Wells Fargo & Company upped their price objective on Bruker from $48.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. The Goldman Sachs Group cut their price objective on Bruker from $40.00 to $35.00 and set a “sell” rating on the stock in a research report on Friday, February 13th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a research report on Friday, March 27th. Finally, TD Cowen cut their price objective on Bruker from $53.00 to $43.00 and set a “hold” rating on the stock in a research report on Friday, February 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $49.38.

Read Our Latest Analysis on BRKR

Bruker Trading Up 2.2%

Bruker stock traded up $0.85 during trading on Tuesday, hitting $39.90. The company had a trading volume of 1,954,948 shares, compared to its average volume of 2,337,056. Bruker has a 1-year low of $28.53 and a 1-year high of $56.22. The company has a current ratio of 1.73, a quick ratio of 0.87 and a debt-to-equity ratio of 0.75. The company’s 50 day simple moving average is $37.63 and its 200-day simple moving average is $41.65. The stock has a market cap of $6.07 billion, a price-to-earnings ratio of -266.00, a price-to-earnings-growth ratio of 2.25 and a beta of 1.20.

Bruker (NASDAQ:BRKR – Get Free Report) last posted its earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.65 by ($0.06). Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The company had revenue of $977.20 million during the quarter, compared to analyst estimates of $964.61 million. During the same quarter last year, the business posted $0.76 EPS. The firm’s revenue for the quarter was down .2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, analysts expect that Bruker will post 2.69 EPS for the current fiscal year.

Insider Activity at Bruker

In related news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $35.44, for a total transaction of $70,880.00. Following the completion of the transaction, the vice president owned 128,443 shares in the company, valued at approximately $4,552,019.92. The trade was a 1.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 27.30% of the company’s stock.

Hedge Funds Weigh In On Bruker

A number of institutional investors and hedge funds have recently modified their holdings of BRKR. Los Angeles Capital Management LLC purchased a new stake in Bruker in the fourth quarter valued at $26,000. Allworth Financial LP lifted its position in Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 257 shares during the last quarter. Parallel Advisors LLC lifted its position in Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 479 shares during the last quarter. Spire Wealth Management lifted its position in Bruker by 85.3% in the third quarter. Spire Wealth Management now owns 1,445 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 665 shares during the last quarter. Finally, Summit Securities Group LLC purchased a new stake in Bruker in the fourth quarter valued at $50,000. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Company Profile

(Get Free Report)

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.